Corona Remedies: Q1 FY27 Revenue up 21.9% to ₹ 422.4 Cr, PAT up 30.1%
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 31 Jul 2026, 05:20 PM IST · BSE ID: a5f9d7dd-67c4-4e03-a788-2a578739cb94
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's first-quarter revenue grew by 21.9% to ₹ 422.4 Cr, and profit increased by 30.1%.
🤖 AI Summary
- Corona Remedies reported unaudited Q1 FY27 Revenue from Operations of ₹ 422.4 Cr.
- Revenue for Q1 FY27 increased by 21.9% year-over-year from ₹ 346.5 Cr in Q1 FY26.
- Profit After Tax for Q1 FY27 was ₹ 60.1 Cr, a 30.1% growth over Q1 FY26's ₹ 46.2 Cr.
- EBITDA for Q1 FY27 stood at ₹ 93.1 Cr, with a margin of 22.0%, up 190 bps YoY.
- New EU-GMP approved Female Hormone Manufacturing Facility inaugurated in Ahmedabad on June 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations
₹ 422.4 Cr
21.9%
Profit After Tax
₹ 60.1 Cr
30.1%
EBITDA Margin
22.0%
190 bps
Profit After Tax Margin
14.2%
90 bps
🏢 How This Affects the Company
The company continues to demonstrate market outperformance, growing 1.9 times the Indian Pharmaceutical Market (IPM) as per MAT June’26, and advanced its market rank to 26th position. The inauguration of a new Female Hormone Plant expands its manufacturing capabilities and therapy leadership in Gynaecology.
Improved Profit After Tax (PAT) margins to 14.2% for Q1 FY27, an increase of 90 bps year-over-year, indicates enhanced profitability. EBITDA margins also expanded by 190 bps to 22.0% for the quarter.
The commissioning of the new EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad enhances production capacity. Integration of the acquired Wokadine brand is underway, affecting supply chain and distribution processes.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results disclosure.
👤
Who Is Affected
All shareholders are affected by the company's financial performance. The robust Q1 FY27 results show revenue growth of 21.9% and PAT growth of 30.1% year-over-year.
🔍
Management Signal
Management's statements indicate a continued focus on operational excellence, brand building, and strategic expansion into core therapeutic areas and new manufacturing capabilities.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — monitor sustained revenue and profit growth.
Updates on Wokadine brand integration progress and market impact.
Further details on utilization and ramp-up of the new Female Hormone Plant.
LOW RISK
The filing reports strong financial performance and operational expansion with no immediate risks identified.
💡 Investor Takeaway
Corona Remedies reported Q1 FY27 Revenue from Operations of ₹ 422.4 Cr, a 21.9% YoY increase, and Profit After Tax of ₹ 60.1 Cr, up 30.1% YoY. The company also inaugurated an EU-GMP approved Female Hormone Manufacturing Facility.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from Operations for Q1 FY27 grew by 21.9% year-over-year to ₹ 422.4 Cr, indicating strong top-line expansion.
- Profit After Tax for Q1 FY27 increased by 30.1% year-over-year to ₹ 60.1 Cr, demonstrating enhanced profitability.
📅 Company Track Record
Corona Remedies reported FY26 revenue up 17.3% to ₹ 1,403.2 Cr and PAT up 33.4% in a filing on May 11, 2026. The company also recommended a ₹ 10 final dividend per equity share for FY26.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Corona Remedies Ltd's Revenue from Operations in Q1 FY27?
Corona Remedies Ltd reported a Revenue from Operations of ₹ 422.4 Cr for the first quarter ended June 30, 2026, marking a 21.9% growth year-over-year.
What was Corona Remedies Ltd's Profit After Tax in Q1 FY27?
The Profit After Tax for Corona Remedies Ltd in Q1 FY27 was ₹ 60.1 Cr, which is a 30.1% increase compared to ₹ 46.2 Cr in Q1 FY26.
What was the EBITDA and EBITDA Margin for Corona Remedies Ltd in Q1 FY27?
Corona Remedies Ltd's EBITDA for Q1 FY27 was ₹ 93.1 Cr, with an EBITDA Margin of 22.0%, an increase of 190 bps year-over-year from 20.1% in Q1 FY26.
Has Corona Remedies Ltd inaugurated any new facilities?
Yes, Corona Remedies Ltd inaugurated and initiated commercialization of its EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad on June 30, 2026.
Questions based on this BSE filing only. For information purposes.